Ignite Creation Date:
2024-05-05 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00047281
Status:
COMPLETED
Last Update Posted:
2017-07-11
First Post:
2002-10-03
Brief Title:
Thalidomide Celecoxib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
01-278
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Patrick Y Wen MD
Responsible Party Title:
Director Center for Neuro-Oncology
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Celgene | INDUSTRY |
| National Cancer Institute NCI | NIH |
| Schering-Plough | INDUSTRY |